REG - Arecor Therapeutics - Director Dealing

Arecor TherapeuticsAnnouncement

29/06/2021 12:10

RNS Number : 5055D
  
Arecor Therapeutics PLC
  
29 June 2021
  
 

Arecor Therapeutics plc
 
("Arecor", the "Company" or the "Group")
 
Director Dealing
 
Cambridge, UK, 29th June 2021. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, today announces that Susan Lowther, Chief Financial Officer, has purchased 12,515 ordinary shares of £0.01 each in the capital of the Company ("Ordinary Shares") at a price of 235 pence per Ordinary Share.
 
Following the transaction, the total beneficial interest of Susan Lowther is 110,681 Ordinary Shares, representing 0.40% of the total voting rights.
 
-ENDS-
 
 
For more information, please contact:



Arecor Therapeutics plc


www.arecor.com




Dr Sarah Howell, Chief Executive Officer


Tel: +44 (0) 1223 426060
Email: info@arecor.com




 


 




Susan Lowther, Chief Financial Officer


Tel: +44 (0) 1223 426060
Email: info@arecor.com




 


 




Mo Noonan, Communications


Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com




 


 




Panmure Gordon (UK) Limited (NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)


Tel: +44 (0) 20 7886 2500
 




 


 




Consilium Strategic Communications


 




Chris Gardner, David Daley, Angela Gray


Tel: +44 (0) 20 3709 5700
Email: arecor@consilium-comms.com



 
Notes to Editors
 
About Arecor
Arecor Therapeutics plc is a biopharmaceutical company transforming patient care by bringing innovative medicines to market.  Through the enhancement of existing medicines using our Arestat™ technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies.  Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.
 
For further details please see our website, www.arecor.com
 
 
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
 



  1


Details of the person discharging managerial responsibilities/person closely associated




a)


Name


Susan Lowther 




2


Reason for the notification




a)


Position/status


Chief Financial Officer




b)


Initial notification/Amendment


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


Arecor Therapeutics plc




b)


LEI


98450093D12I3A8DDD58




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument


Ordinary Shares




b)


Identification Code


GB00BMWLM973




c)


Nature of the transaction


Purchase of shares


















d)


Price(s) and volume(s)


 235 pence and 12,515 Ordinary Shares




e)


Aggregated information
- Aggregated volume
- Aggregated price


N/A




f)


Date of the transaction


29 June 2021




g)


Place of the transaction


London Stock Exchange, AIM



 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHGZGZVMLFGMZM